[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 17 of about 17
1. Morgan RJ, Synold T, Mamelak A, Lim D, Al-Kadhimi Z, Twardowski P, Leong L, Chow W, Margolin K, Shibata S, Somlo G, Yen Y, Frankel P, Doroshow JH: Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors. Cancer Chemother Pharmacol; 2010 Oct;66(5):927-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Tamoxifen 100 mg po bid, topotecan 0.25, 0.5, 0.75, or 1.0 mg/m(2)/d IV, administered as a 72 h continuous infusion on days 1-3, followed by carboplatin AUC = 3, IV on day 3.
  • The tumors included glioblastoma (6), anaplastic astrocytoma (2), metastatic non-small cell (3), small cell lung (2), and one each with medulloblastoma, ependymoma, and metastatic breast or colon carcinoma.
  • CONCLUSIONS: The recommended phase II doses are: tamoxifen 100 mg po bid, topotecan 0.75 mg/m(2)/d IV continuous infusion for 72 h, followed by carboplatin AUC = 3 IV on day 3.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Anticancer Drugs. 1998 Aug;9(7):581-6 [9773800.001]
  • [Cites] J Neurooncol. 1999 Feb;41(3):285-9 [10359149.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):208-15 [18316473.001]
  • [Cites] Eur J Pharmacol. 2001 Jan 19;412(1):21-5 [11166732.001]
  • [Cites] Cancer Invest. 2002;20(3):293-302 [12025223.001]
  • [Cites] Cancer. 2003 May 1;97(9 Suppl):2381-6 [12712460.001]
  • [Cites] Cancer. 1982 Jan 1;49(1):12-8 [6274499.001]
  • [Cites] Onkologie. 1983 Apr;6(2):58-61 [6223253.001]
  • [Cites] J Neurooncol. 1983;1(2):139-44 [6678966.001]
  • [Cites] Int J Cancer. 1988 Sep 15;42(3):382-8 [3417367.001]
  • [Cites] Cancer Chemother Pharmacol. 1990;25(5):382-3 [2407368.001]
  • [Cites] Br J Cancer. 1991 Apr;63(4):641-5 [2021551.001]
  • [Cites] Cancer Res. 1991 Sep 15;51(18):4837-44 [1893376.001]
  • [Cites] J Neurooncol. 1991 Apr;10(2):173-7 [1716670.001]
  • [Cites] Cancer. 1992 Feb 15;69(4):972-80 [1735089.001]
  • [Cites] Cancer Metastasis Rev. 1991 Dec;10(4):335-41 [1786634.001]
  • [Cites] Neurosurgery. 1992 Jun;30(6):897-902; discussion 902-3 [1377370.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;30(4):251-60 [1643692.001]
  • [Cites] Invest New Drugs. 1992 Nov;10(4):239-53 [1487397.001]
  • [Cites] Neurosurgery. 1993 Mar;32(3):485-9; discussion 489-90 [8384328.001]
  • [Cites] Eur J Cancer. 1993;29A(12):1696-9 [7691116.001]
  • [Cites] Cancer Res. 1994 Oct 1;54(19):5118-22 [7923128.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;37(3):195-202 [8529278.001]
  • [Cites] J Natl Cancer Inst. 1996 Jun 5;88(11):734-41 [8637027.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(2):215-20 [8686548.001]
  • [Cites] Cancer. 1996 Aug 1;78(3):527-31 [8697400.001]
  • [Cites] J Chromatogr B Biomed Appl. 1996 Apr 12;678(2):309-15 [8738036.001]
  • [Cites] Neurosurgery. 1996 Mar;38(3):587-90; discussion 590-1 [8837815.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3074-84 [8955652.001]
  • [Cites] Am J Clin Oncol. 1997 Jun;20(3):303-7 [9167759.001]
  • [Cites] J Neurooncol. 1997 Nov;35(2):161-7 [9266454.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3121-8 [9294475.001]
  • [Cites] Semin Oncol. 1997 Aug;24(4 Suppl 12):S12-52-S12-55 [9331122.001]
  • [Cites] Semin Oncol. 1997 Dec;24(6 Suppl 20):S20-11-S20-26 [9425957.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;41(4):307-16 [9488600.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;41(5):385-90 [9523734.001]
  • [Cites] J Neurooncol. 1998 May;38(1):59-68 [9540058.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1998 May;78(1):91-3 [9605456.001]
  • [Cites] Clin Cancer Res. 1996 Apr;2(4):619-22 [9816211.001]
  • (PMID = 20107803.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA033572; United States / NCI NIH HHS / CA / P30 CA033572-26; United States / NCI NIH HHS / CA / CA 33572
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen; 7M7YKX2N15 / Topotecan; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ NIHMS335377; NLM/ PMC3265324
  •  go-up   go-down


2. Okcu MF, Selvan M, Wang LE, Stout L, Erana R, Airewele G, Adatto P, Hess K, Ali-Osman F, Groves M, Yung AW, Levin VA, Wei Q, Bondy M: Glutathione S-transferase polymorphisms and survival in primary malignant glioma. Clin Cancer Res; 2004 Apr 15;10(8):2618-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glutathione S-transferase polymorphisms and survival in primary malignant glioma.
  • RESULTS: For patients with anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and anaplastic ependymoma (n = 78), patients with GSTP1*A/*A-M1 null genotype survived longer than did the rest of the group (median survival "not achieved," and 41 months, respectively; P = 0.06).
  • CONCLUSIONS: In patients with anaplastic astrocytoma, anaplastic oligodendroglioma, and anaplastic oligoastrocytoma, combination of germ-line GSTP1*A/*A and GSTM1 null genotype confers a survival advantage.
  • Patients with this genotype also have an increased risk of adverse events secondary to chemotherapy that primarily comprised nitrosourea alkylating agents.
  • [MeSH-minor] Adult. Astrocytoma / genetics. Ependymoma / genetics. Female. Genotype. Glutathione S-Transferase pi. Humans. Logistic Models. Male. Middle Aged. Neoplasm Metastasis. Oligodendroglioma / genetics. Polymerase Chain Reaction. Polymorphism, Restriction Fragment Length. Proportional Hazards Models. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15102663.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA70917
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


3. Ribalta T, McCutcheon IE, Neto AG, Gupta D, Kumar AJ, Biddle DA, Langford LA, Bruner JM, Leeds NE, Fuller GN: Textiloma (gossypiboma) mimicking recurrent intracranial tumor. Arch Pathol Lab Med; 2004 Jul;128(7):749-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Resorbable and nonresorbable hemostatic agents have been reported to cause symptomatic mass lesions, most commonly following intra-abdominal surgery.
  • Histologic examination typically shows a core of degenerating hemostatic agent surrounded by an inflammatory reaction.
  • Each agent exhibits distinctive morphologic features that often permit specific identification.
  • OBJECTIVES: The aims of this study were to (1) identify cases of histologically proven cases of textiloma in neurosurgical operations, (2) characterize the specific hemostatic agent associated with textiloma formation, and (3) characterize the preoperative magnetic resonance imaging appearance of textiloma.
  • The primary neoplasm was different in each case and included pituitary adenoma, tanycytic ependymoma, anaplastic astrocytoma, gliosarcoma, and oligodendroglioma.
  • Textilomas included all categories of resorbable hemostatic agent.
  • Microfibrillar collagen (Avitene) textilomas were associated with a striking eosinophil infiltration that was not seen with any other hemostatic agent.
  • CONCLUSIONS: Hemostatic agents may produce clinically symptomatic, radiologically apparent mass lesions.
  • [MeSH-minor] Adolescent. Adult. Cellulose, Oxidized. Collagen. Cotton Fiber. Diagnosis, Differential. Female. Gelatin Sponge, Absorbable. Hemostatics. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Radiation Injuries / diagnosis

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15214828.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cellulose, Oxidized; 0 / Hemostatics; 82347-53-3 / Surgicel; 9007-34-5 / Collagen
  •  go-up   go-down


Advertisement
4. Gilbert MR, Ruda R, Soffietti R: Ependymomas in adults. Curr Neurol Neurosci Rep; 2010 May;10(3):240-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They occur most commonly in the spinal cord, where histopathologic evaluation is critical to differentiate the grade I myxopapillary ependymoma from the grade II ependymoma or grade III anaplastic ependymoma.
  • For myxopapillary ependymoma, complete removal while maintaining capsule integrity may be curative.
  • Ongoing laboratory studies have uncovered important signal transduction pathways that may be better therapeutic targets, leading to the development of clinical trials using targeted agents.
  • [MeSH-major] Central Nervous System Neoplasms. Ependymoma
  • [MeSH-minor] Adult. Epigenesis, Genetic. Humans

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurochir (Wien). 2004 Nov;146(11):1255-8 [15365794.001]
  • [Cites] Cancer Lett. 2005 Sep 8;227(1):75-81 [16051033.001]
  • [Cites] Neurology. 2009 Nov 17;73(20):1677-80 [19917990.001]
  • [Cites] Neuro Oncol. 2005 Jan;7(1):20-31 [15701279.001]
  • [Cites] Neurology. 2003 Oct 14;61(7):1019-20 [14557591.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):665-9 [16021573.001]
  • [Cites] Am J Clin Oncol. 2002 Apr;25(2):117-22 [11943886.001]
  • [Cites] Neuro Oncol. 2005 Jul;7(3):254-9 [16053700.001]
  • [Cites] J Pathol. 2002 Jun;197(2):238-44 [12015749.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5223-33 [17114655.001]
  • [Cites] Pediatr Neurol. 2001 Feb;24(2):117-21 [11275460.001]
  • [Cites] Brain Pathol. 2001 Apr;11(2):133-43 [11303789.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Mar;12(3):323-7 [3082807.001]
  • [Cites] Childs Nerv Syst. 2009 Oct;25(10):1275-82 [19212772.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1199-204 [17689025.001]
  • [Cites] Mod Pathol. 2008 Feb;21(2):165-77 [18084249.001]
  • [Cites] J Neurooncol. 2002 Dec;60(3):255-68 [12510777.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2070-9 [16609018.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Apr 1;166(1):74-81 [16616114.001]
  • [Cites] Cancer. 2009 Oct 15;115(20):4775-82 [19569246.001]
  • [Cites] J Neurooncol. 2000 May;47(3):211-8 [11016737.001]
  • [Cites] J Neurooncol. 1999;45(1):61-7 [10728911.001]
  • [Cites] J Neurooncol. 2005 Dec;75(3):287-99 [16195801.001]
  • [Cites] J Med Genet. 2005 Jan;42(1):31-7 [15635072.001]
  • [Cites] J Neurosurg. 2005 Jul;103(1):31-7 [16121970.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Jun;66(6):505-16 [17549010.001]
  • [Cites] Childs Nerv Syst. 2009 Oct;25(10):1195-201 [19536551.001]
  • [Cites] J Comput Assist Tomogr. 2004 May-Jun;28(3):407-13 [15100549.001]
  • [Cites] Br J Cancer. 2008 Oct 7;99(7):1129-35 [18797459.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):953-8 [9869215.001]
  • [Cites] J Chemother. 2008 Apr;20(2):263-8 [18467255.001]
  • [Cites] Neuropathology. 2006 Oct;26(5):422-8 [17080719.001]
  • [Cites] J Exp Clin Cancer Res. 2004 Jun;23(2):201-6 [15354403.001]
  • [Cites] Brain. 2007 May;130(Pt 5):1338-49 [17449478.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):143-8 [15912507.001]
  • [Cites] Acta Neurochir (Wien). 2009 Aug;151(8):947-60 [19499166.001]
  • [Cites] Int J Cancer. 2004 Jul 1;110(4):542-9 [15122586.001]
  • [Cites] Curr Opin Neurol. 2008 Dec;21(6):754-61 [18989122.001]
  • [Cites] Childs Nerv Syst. 2009 Oct;25(10):1185-93 [19212775.001]
  • [Cites] Pediatr Blood Cancer. 2004 May;42(5):457-60 [15049020.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):323-35 [16226707.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1221-9 [15022290.001]
  • [Cites] J Neurosurg. 2009 Apr;110(4):725-9 [19061350.001]
  • [Cites] J Surg Res. 2009 Oct;156(2):340-51 [19577759.001]
  • [Cites] Neurosurgery. 1999 Apr;44(4):721-31 [10201296.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Oct;13(10):1457-62 [3624024.001]
  • [Cites] Spine (Phila Pa 1976). 2009 Oct 1;34(21):E756-60 [19934795.001]
  • [Cites] Lancet Oncol. 2009 Mar;10(3):258-66 [19274783.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1721-7 [14578171.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Oct;12(10):1765-9 [3759528.001]
  • [Cites] Cancer. 2008 Jul 1;113(1):175-85 [18470910.001]
  • [Cites] J Neurosurg. 1983 Oct;59(4):652-9 [6886786.001]
  • [Cites] Acta Neuropathol. 2007 Mar;113(3):325-37 [17265049.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1983 Jul;9(7):1093-6 [6863076.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3054-64 [12374672.001]
  • [Cites] Neurosurgery. 1991 May;28(5):666-71; discussion 671-2 [1876244.001]
  • [Cites] Am J Clin Oncol. 2006 Feb;29(1):106-7 [16462515.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Sep;67(9):911-20 [18716553.001]
  • (PMID = 20425040.001).
  • [ISSN] 1534-6293
  • [Journal-full-title] Current neurology and neuroscience reports
  • [ISO-abbreviation] Curr Neurol Neurosci Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 62
  •  go-up   go-down


5. Kanamori M, Kumabe T, Saito R, Yamashita Y, Sonoda Y, Tominaga T: [The safety of combination chemotherapy with ifosfamide, cisplatin, and etoposide (ICE): single-institution retrospective review of 108 cases]. No Shinkei Geka; 2010 Nov;38(11):997-1005
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histological diagnosis was newly diagnosed or recurrent germ cell tumor in 45 cases, medulloblastoma in 19, primitive neuroectodermal tumor (PNET) in 7, anaplastic ependymoma in 6, recurrent glioblastoma in 13, and others in 18 cases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Brain Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Child. Child, Preschool. Cisplatin / administration & dosage. Cisplatin / adverse effects. Ependymoma / drug therapy. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Glioblastoma / drug therapy. Hematologic Diseases / chemically induced. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Infant. Male. Medulloblastoma / drug therapy. Middle Aged. Neoplasms, Germ Cell and Embryonal / drug therapy. Neuroectodermal Tumors, Primitive / drug therapy. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21081811.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


6. Dreyer ZE, Kadota RP, Stewart CF, Friedman HS, Mahoney DH, Kun LE, McCluggage CW, Burger PC, Kepner J, Heideman RL, Pediatric Oncology Group: Phase 2 study of idarubicin in pediatric brain tumors: Pediatric Oncology Group study POG 9237. Neuro Oncol; 2003 Oct;5(4):261-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients were stratified by tumor types into 6 categories: stratum 1, low-grade astrocytoma; stratum 2, malignant glioma (glioblastoma multiforme and anaplastic astrocytoma); stratum 3, medulloblastoma; stratum 4, brainstem glioma; stratum 5, ependymoma; and stratum 6, miscellaneous malignant tumors not included in the previous diagnoses.
  • The systemic clearance data for IDA and IDOL were nearly identical to those published on patients with leukemia, and the plasma elimination of the IDOL metabolite was substantially longer than that of the parent drug IDA.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Idarubicin / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Male

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14565163.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] ZRP63D75JW / Idarubicin
  • [Other-IDs] NLM/ PMC1920677
  •  go-up   go-down


7. Turner CD, Gururangan S, Eastwood J, Bottom K, Watral M, Beason R, McLendon RE, Friedman AH, Tourt-Uhlig S, Miller LL, Friedman HS: Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro Oncol; 2002 04;4(2):102-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
  • A phase II study of irinotecan (CPT-11) was conducted at Duke University Medical Center, Durham, NC, to evaluate the activity of this agent in children with high-risk malignant brain tumors.
  • A total of 22 children were enrolled in this study, including 13 with histologically verified recurrent malignant brain tumors (glioblastoma multiforme [GBM] 4, anaplastic astrocytoma 1, ependymoma 5, and medulloblastoma/primitive neuroectodermal tumor 3), 5 with recurrent diffuse pontine glioma, and 4 with newly diagnosed GBM.
  • Patients with newly diagnosed tumors initially received 3 cycles of treatment to assess tumor response and then were allowed radiotherapy at physician's choice; patients who demonstrated a response to CPT-11 prior to radiotherapy were allowed to continue the drug after radiation until disease progression or unacceptable toxicity.
  • A 25% to 50% dose reduction was made for grade III-IV toxicity.
  • Responses were seen in 4 of 9 patients with GBM or anaplastic astrocytoma (44%; 95% confidence interval, 11%-82%) (complete response in 2 patients with recurrent GBM lasting 9 months and 48+ months; partial response in one patient with a newly diagnosed midbrain GBM lasting 18 months prior to radiotherapy; and partial response lasting 11 months in 1 patient with recurrent anaplastic astrocytoma), 1 of 5 patients with recurrent ependymoma (partial response initially followed by stable disease lasting 11 months), and none of 5 patients with recurrent diffuse pontine glioma.
  • Toxicity was mainly myelosuppression, with 12 of 22 patients (50%) suffering grade II-IV neutropenia.
  • CPT-11, given in this schedule, appears to be active in children with malignant glioma, medulloblastoma, and ependymoma with acceptable toxicity.
  • Ongoing studies will demonstrate if activity of CPT-11 can be enhanced when combined with alkylating agents, including carmustine and temozolomide.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Brain Neoplasms / drug therapy. Camptothecin / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Astrocytoma / drug therapy. Child. Child, Preschool. Drug Administration Schedule. Ependymoma / drug therapy. Female. Glioblastoma / drug therapy. Glioma. Humans. Magnetic Resonance Imaging. Male. Medulloblastoma / drug therapy. Topoisomerase Inhibitors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11916501.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Topoisomerase Inhibitors; 0H43101T0J / irinotecan; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC1920653
  •  go-up   go-down


8. Marcus KJ, Goumnerova L, Billett AL, Lavally B, Scott RM, Bishop K, Xu R, Young Poussaint T, Kieran M, Kooy H, Pomeroy SL, Tarbell NJ: Stereotactic radiotherapy for localized low-grade gliomas in children: final results of a prospective trial. Int J Radiat Oncol Biol Phys; 2005 Feb 1;61(2):374-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 81 patients, 50 had low-grade astrocytoma, 23 had residual or recurrent craniopharyngioma, 4 had posterior fossa ependymoma, and 4 had other histologic types.
  • Two of the patients with local progression had pathologic progression to anaplastic astrocytoma 3 and 7 years after initial SRT.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Confidence Intervals. Disease Progression. Disease-Free Survival. Female. Humans. Male. Neoplasm Recurrence, Local / drug therapy. Prospective Studies. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667955.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Oshiro S, Tsugu H, Komatsu F, Ohmura T, Ohta M, Sakamoto S, Fukushima T, Inoue T: Efficacy of temozolomide treatment in patients with high-grade glioma. Anticancer Res; 2009 Mar;29(3):911-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: The subjects comprised ten patients with high-grade glioma [glioblastoma multiforme (GBM), n=3, gliosarcoma (GS), n=1, anaplastic oligodendroglioma (AO), n=3, anaplastic mixed oligoastrocytoma (AOA), n=1, and anaplastic ependymoma (AE), n=2].
  • RESULTS: Partial response (PR) to TMZ therapy was achieved by four out of the ten patients (objective response rate, 40%), while three patients displayed stable disease (SD) and three showed disease progression (PD).
  • Assessing the true efficacy of TMZ will require a larger study with comparison of long-term outcomes between other agents or combined therapeutic modalities.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Gliosarcoma / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Combined Modality Therapy. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Etoposide / administration & dosage. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Treatment Outcome. Tumor Necrosis Factor-alpha / therapeutic use

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19414327.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


10. Benesch M, Siegler N, Hoff Kv, Lassay L, Kropshofer G, Müller H, Sommer C, Rutkowski S, Fleischhack G, Urban C: Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study. Anticancer Drugs; 2009 Oct;20(9):794-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nineteen heavily pretreated patients (males, n = 14; females, n = 5; median age at diagnosis 8.5 years; range, 1.4-22 years) were given intrathecal liposomal cytarabine on a compassionate use basis for recurrent refractory medulloblastoma (n = 12), mixed germ cell tumor (n = 2), central nervous system primitive neuroectodermal tumors of the pons (n = 1), anaplastic ependymoma (n = 1), anaplastic oligodendroglioma (n = 1), atypical teratoid rhabdoid tumor (n = 1), or rhabdoid papillary meningioma (n = 1).
  • Proof of efficacy requires a prospective single-agent phase II study.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Brain Neoplasms / drug therapy. Cytarabine / administration & dosage. Cytarabine / adverse effects
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Compassionate Use Trials. Delayed-Action Preparations. Drug Resistance, Neoplasm. Female. Humans. Infant. Injections, Spinal. Liposomes / administration & dosage. Male. Retrospective Studies. Salvage Therapy. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19617818.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Delayed-Action Preparations; 0 / Liposomes; 04079A1RDZ / Cytarabine
  •  go-up   go-down


11. Matsuo M, Yonemitsu N, Zaitsu M, Ishii K, Hamasaki Y, Fukuyama K, Tabuchi K, Miyazaki S: Expression of prostaglandin H synthase-2 in human brain tumors. Acta Neuropathol; 2001 Aug;102(2):181-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Numerous studies have demonstrated that prostaglandin H synthase-2 (PHS-2) is involved in gastrointestinal carcinogenesis, and that nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit PHS, can reduce the risk of colon cancer.
  • In brain tumors, elevated prostaglandin production and its correlation to anaplastic grade of gliomas have been demonstrated.
  • All surgical specimens, except an ependymoma, which expressed both isozymes equally, expressed PHS-2 mRNA predominantly.
  • Immunohistochemistry of various types of brain tumors, including six glioblastomas, nine astrocytomas, six meningiomas, five medulloblastomas, four craniopharyngiomas, three ependymomas, three neurinomas, two oligodendrogliomas, two malignant lymphomas, two dysembryoplastic neuroepitherial tumors and one metastatic brain tumor showed PHS-2 staining in most cases.
  • [MeSH-minor] Adolescent. Adult. Aged. Brain / enzymology. Brain / pathology. Cell Compartmentation / genetics. Child. Child, Preschool. Cyclooxygenase 1. Cyclooxygenase 2. Female. Humans. Immunohistochemistry. Male. Membrane Proteins. Middle Aged. Neuroglia / enzymology. Neuroglia / pathology. Neurons / enzymology. Neurons / pathology. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11563634.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / Membrane Proteins; 0 / Prostaglandins; 0 / RNA, Messenger; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS1 protein, human; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


12. Nishio S, Morioka T, Fujii K, Inamura T, Fukui M: Spinal cord gliomas: management and outcome with reference to adjuvant therapy. J Clin Neurosci; 2000 Jan;7(1):20-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors review their experience with 19 consecutive cases with either astrocytic tumour (glioblastoma multiforme one, anaplastic astrocytoma one, astrocytoma 4, pilocytic astrocytoma 4) or ependymoma (10 tumours in 9 patients) of the spinal cord who were treated during the period from 1982 to 1996.
  • Eight out of 9 patients with an ependymoma have remained alive for 3.0-12.3 years, while one committed suicide 2 years after surgery.
  • [MeSH-major] Astrocytoma / surgery. Ependymoma / surgery. Spinal Cord Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Child, Preschool. Female. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Glioblastoma / surgery. Humans. Infant. Male. Middle Aged. Postoperative Care. Radiotherapy, Adjuvant. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10847645.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] SCOTLAND
  •  go-up   go-down


13. Kieran MW, Packer RJ, Onar A, Blaney SM, Phillips P, Pollack IF, Geyer JR, Gururangan S, Banerjee A, Goldman S, Turner CD, Belasco JB, Broniscer A, Zhu Y, Frank E, Kirschmeier P, Statkevich P, Yver A, Boyett JM, Kun LE: Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. J Clin Oncol; 2007 Jul 20;25(21):3137-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both radiographic response (one anaplastic astrocytoma) and stable disease (one medulloblastoma, two high-grade and four low-grade gliomas, one ependymoma, and one sarcoma) were noted, and seven patients remained on treatment for 1 year or longer.
  • [MeSH-major] Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / mortality. Enzyme Inhibitors / pharmacokinetics. Farnesyltranstransferase / antagonists & inhibitors. Neoplasm Invasiveness / pathology. Piperidines / pharmacokinetics. Pyridines / pharmacokinetics
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Child. Child, Preschool. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Male. Maximum Tolerated Dose. Neoplasm Staging. Risk Assessment. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17634493.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA81457
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Piperidines; 0 / Pyridines; 193275-84-2 / lonafarnib; EC 2.5.1.29 / Farnesyltranstransferase
  •  go-up   go-down


14. Poulsen HS: [Gliomas in adults: primary non-surgical treatment]. Ugeskr Laeger; 2006 Nov 20;168(47):4082-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anaplastic astrocytomas should be treated with postoperative radiation therapy with or without adjuvant chemotherapy.
  • Anaplastic oligodendroglioma should be treated with radiation therapy only.
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Chemotherapy, Adjuvant. Ependymoma / drug therapy. Ependymoma / radiotherapy. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Humans. Oligodendroglioma / drug therapy. Oligodendroglioma / radiotherapy. Radiotherapy Dosage. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17134603.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 10
  •  go-up   go-down


15. Reuther FJ, Löhler J, Herms J, Hugo HH, Schindler C, Leithäuser F, Melzner I, Möller P, Scheil S: Low incidence of SV40-like sequences in ependymal tumours. J Pathol; 2001 Dec;195(5):580-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Between 1955 and 1963, millions of children and adults were exposed to SV40-contaminated poliovirus vaccines.
  • Only three (5%) of the tumours--including 24 classical, 20 anaplastic, and 12 myxopapillary ependymomas; one subependymoma; and five ependymoblastomas--revealed subgenomic SV40 sequences.
  • The positive tumours represent 7% of grade II and III ependymomas (two paediatric and one adult tumour).
  • DNA sequencing of the PCR product revealed identical sequences of SV40 in the positive ependymal tumours.
  • These differences may reflect different degrees of exposure to SV40-contaminated polio vaccine.
  • [MeSH-major] Ependymoma / virology. Simian virus 40 / isolation & purification
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. DNA, Viral / analysis. Drug Contamination. Germany / epidemiology. Humans. Incidence. Infant. Male. Middle Aged. Poliovirus Vaccines. Polymerase Chain Reaction / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 John Wiley & Sons, Ltd.
  • (PMID = 11745694.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Poliovirus Vaccines
  • [Number-of-references] 27
  •  go-up   go-down


16. Green RM, Cloughesy TF, Stupp R, DeAngelis LM, Woyshner EA, Ney DE, Lassman AB: Bevacizumab for recurrent ependymoma. Neurology; 2009 Nov 17;73(20):1677-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab for recurrent ependymoma.
  • BACKGROUND: Ependymoma is a rare type of glioma, representing 5% of all CNS malignancies.
  • At recurrence, ependymoma is notoriously refractory to therapy and the prognosis is poor.
  • METHODS: In this Institutional Review Board-approved study, we retrospectively analyzed the records of 8 adult patients treated for recurrent ependymoma and anaplastic ependymoma with bevacizumab containing chemotherapy regimens.

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Acta Neuropathol. 2005 Feb;109(2):211-6 [15614581.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1542-50 [17705175.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):159-67 [19019565.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):143-8 [15912507.001]
  • (PMID = 19917990.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / UO1 CA-105663-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  • [Other-IDs] NLM/ PMC2788805
  •  go-up   go-down


17. De Sio L, Milano GM, Castellano A, Jenkner A, Fidani P, Dominici C, Donfrancesco A: Temozolomide in resistant or relapsed pediatric solid tumors. Pediatr Blood Cancer; 2006 Jul;47(1):30-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: We report the off-label study aimed at investigating the use of temozolomide (TMZ) as single agent in relapsed or resistant pediatric solid tumors.
  • The drug was administered at the dose of 215 mg/m2/day x 5 days or 180 mg/m2/day x 5 days in patients with prior craniospinal irradiation (CSI) or autologous bone marrow transplantation (ABMT).
  • Tumor types were: neuroblastoma (NB; n = 17), medulloblastoma (MB; 8), brain stem glioma (BSG; 8), extraosseous Ewing's sarcoma/peripheral neuroectodermal tumor (EOES; 4), Ewing's sarcoma (ES; 4), anaplastic astrocytoma (AA; 3), rhabdomyosarcoma (RMS; 2), ependymoma (EP; 2), cerebral primitive neuroectodermal tumor (cPNET; 2), hepatocarcinoma (HC; 1), and osteosarcoma (OS; 1).
  • RESULTS: Objective response-rate (CR + PR + MR) in our series was 13.4% (1.9% CR, 3.8% PR, and 7.7% MR), SD occurred in 38.4% of patients and 48% had PD.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / analogs & derivatives. Drug Resistance, Neoplasm. Neoplasm Recurrence, Local / drug therapy. Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Humans. Male. Survival Analysis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • [ErratumIn] Pediatr Blood Cancer. 2006 Oct 15;47(5):647-8
  • (PMID = 16047361.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down






Advertisement